ASH 2021 | Standardization MRD monitoring in clinical trials
Luciano Costa
• 12 Dec 2021
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, considers the significance of harmonizing minimal residual disease (MRD) assessment protocols in multiple myeloma clinical trials. Current MRD monitoring techniques are inconsistent across clinical trials due to differences in who are assessed and how it is reported. Measuring MRD is crucial to monitor patients and to develop guided therapies and standardization of testing in clinical trials will enable researchers to accurately collect and assess data. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
